{"id":"mazindol","rwe":[{"pmid":"41745708","year":"2026","title":"Consensus Molecules Associated with Parkinson's Disease.","finding":"","journal":"Neurology international","studyType":"Clinical Study"},{"pmid":"41667893","year":"2026","title":"Mazindol Immediate-Release/Sustained-Release (IR/SR): A 50-Year Legacy of Multifaceted Mechanisms and Emerging Therapeutic Potential.","finding":"","journal":"Clinical drug investigation","studyType":"Clinical Study"},{"pmid":"41262092","year":"2025","title":"Preoperative Management with Mazindol for Obese Women Diagnosed with Endometrial Carcinoma Undergoing Robot-assisted Hysterectomy: A Pilot Case Series and Literature Review.","finding":"","journal":"Gynecology and minimally invasive therapy","studyType":"Clinical Study"},{"pmid":"41130371","year":"2026","title":"Glucagon-like Peptide-1 Receptor Agonist Use and Risk of Cataract Development.","finding":"","journal":"American journal of ophthalmology","studyType":"Clinical Study"},{"pmid":"41129133","year":"2025","title":"Glucagon-Like Peptide-1 Receptor Agonists and Age-Related Macular Degeneration.","finding":"","journal":"JAMA ophthalmology","studyType":"Clinical Study"}],"tags":[{"label":"mazindol","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Sodium-dependent noradrenaline transporter","category":"target"},{"label":"SLC6A2","category":"gene"},{"label":"SLC6A3","category":"gene"},{"label":"SLC6A4","category":"gene"},{"label":"A08AA05","category":"atc"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Obesity","category":"indication"},{"label":"Approved 1970s","category":"decade"},{"label":"Adrenergic Agents","category":"pharmacology"},{"label":"Adrenergic Uptake Inhibitors","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Central Nervous System Stimulants","category":"pharmacology"},{"label":"Dopamine Agents","category":"pharmacology"},{"label":"Dopamine Uptake Inhibitors","category":"pharmacology"},{"label":"Membrane Transport Modulators","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Neurotransmitter Uptake Inhibitors","category":"pharmacology"}],"phase":"marketed","safety":{"drugInteractions":[{"url":"/drug/ioflupane-i-123","drug":"Ioflupane I-123","action":"Monitor closely","effect":"May interact with Ioflupane I-123","source":"DrugCentral","drugSlug":"ioflupane-i-123"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=MAZINDOL","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:46:00.660228+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:46:06.241371+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MAZINDOL","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:46:06.712079+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Monoamine transporter inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:46:07.944632+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL781/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:46:07.602858+00:00"}},"allNames":"sanorex","offLabel":[],"synonyms":["mazindol","mazanor","mazildene"],"timeline":[{"date":"1973-06-14","type":"positive","source":"DrugCentral","milestone":"FDA approval"}],"aiSummary":"Sanorex (MAZINDOL) is a small molecule drug that targets the sodium-dependent noradrenaline transporter. Originally developed and currently owned by Novartis, it was FDA-approved in 1973 for the treatment of obesity. As an off-patent medication with no active Orange Book patents, Sanorex is available as a branded product. Key safety considerations include its potential impact on blood pressure and heart rate. Sanorex is a non-stimulant medication that works by increasing the levels of norepinephrine in the brain, which helps to suppress appetite and increase feelings of fullness.","approvals":[{"date":"1973-06-14","orphan":false,"company":"","regulator":"FDA"}],"brandName":"Sanorex","ecosystem":[{"indication":"Obesity","otherDrugs":[{"name":"amfetamine","slug":"amfetamine","company":"Ucb Inc"},{"name":"benzphetamine","slug":"benzphetamine","company":"Pharmacia And Upjohn"},{"name":"bupropion","slug":"bupropion","company":"Glaxosmithkline"},{"name":"chlorphentermine","slug":"chlorphentermine","company":"Parke Davis"}],"globalPrevalence":890000000}],"mechanism":{"target":"Sodium-dependent noradrenaline transporter","novelty":"Follow-on","targets":[{"gene":"SLC6A2","source":"DrugCentral","target":"Sodium-dependent noradrenaline transporter","protein":"Sodium-dependent noradrenaline transporter"},{"gene":"SLC6A3","source":"DrugCentral","target":"Sodium-dependent dopamine transporter","protein":"Sodium-dependent dopamine transporter"},{"gene":"SLC6A4","source":"DrugCentral","target":"Sodium-dependent serotonin transporter","protein":"Sodium-dependent serotonin transporter"},{"gene":"SIGMAR1","source":"DrugCentral","target":"Sigma non-opioid intracellular receptor 1","protein":"Sigma non-opioid intracellular receptor 1"},{"gene":"HRH1","source":"DrugCentral","target":"Histamine H1 receptor","protein":"Histamine H1 receptor"}],"modality":"Small Molecule","drugClass":"mazindol","explanation":"","oneSentence":"","technicalDetail":"Sanorex (mazindol) is a norepinephrine-dopamine reuptake inhibitor that selectively targets the sodium-dependent noradrenaline transporter (NET), increasing the synaptic concentration of norepinephrine and modulating appetite and satiety centers in the brain."},"commercial":{"launchDate":"1973","_launchSource":"DrugCentral (FDA 1973-06-14, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1640","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=MAZINDOL","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MAZINDOL","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T12:30:45.035591","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:46:09.147005+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"phentermine","drugSlug":"phentermine","fdaApproval":"1959-05-04","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"fenfluramine","drugSlug":"fenfluramine","fdaApproval":"2020-06-25","patentExpiry":"Nov 3, 2033","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"diethylpropion","drugSlug":"diethylpropion","fdaApproval":"1959-08-06","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"sibutramine","drugSlug":"sibutramine","fdaApproval":"1997-11-22","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"lorcaserin","drugSlug":"lorcaserin","fdaApproval":"2012-06-27","relationship":"same-class"},{"drugName":"setmelanotide","drugSlug":"setmelanotide","fdaApproval":"2020-11-25","patentExpiry":"Oct 13, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"topiramate","drugSlug":"topiramate","fdaApproval":"1996-12-24","patentExpiry":"Nov 16, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"ephedrine","drugSlug":"ephedrine","fdaApproval":"","patentExpiry":"May 16, 2040","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"bupropion","drugSlug":"bupropion","fdaApproval":"1985-12-30","patentExpiry":"Jun 27, 2026","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"naltrexone","drugSlug":"naltrexone","fdaApproval":"1984-11-20","patentExpiry":"Oct 15, 2029","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"mazindol","indications":{"approved":[{"name":"Obesity","source":"DrugCentral","snomedId":414916001,"regulator":"FDA","usPrevalence":100000000,"globalPrevalence":890000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2024"}],"offLabel":[],"pipeline":[]},"currentOwner":"Novartis","drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"phentermine","brandName":"phentermine","genericName":"phentermine","approvalYear":"1959","relationship":"same-class"},{"drugId":"fenfluramine","brandName":"fenfluramine","genericName":"fenfluramine","approvalYear":"2020","relationship":"same-class"},{"drugId":"diethylpropion","brandName":"diethylpropion","genericName":"diethylpropion","approvalYear":"1959","relationship":"same-class"},{"drugId":"sibutramine","brandName":"sibutramine","genericName":"sibutramine","approvalYear":"1997","relationship":"same-class"},{"drugId":"lorcaserin","brandName":"lorcaserin","genericName":"lorcaserin","approvalYear":"2012","relationship":"same-class"},{"drugId":"setmelanotide","brandName":"setmelanotide","genericName":"setmelanotide","approvalYear":"2020","relationship":"same-class"},{"drugId":"topiramate","brandName":"topiramate","genericName":"topiramate","approvalYear":"1996","relationship":"same-class"},{"drugId":"ephedrine","brandName":"ephedrine","genericName":"ephedrine","approvalYear":"","relationship":"same-class"},{"drugId":"bupropion","brandName":"bupropion","genericName":"bupropion","approvalYear":"1985","relationship":"same-class"},{"drugId":"naltrexone","brandName":"naltrexone","genericName":"naltrexone","approvalYear":"1984","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05914194","phase":"PHASE3","title":"A Eight-Week Study of NLS-2 (Mazindol Extended Release) in Participants With Narcolepsy Type 1","status":"NOT_YET_RECRUITING","sponsor":"NLS Pharmaceutics","startDate":"2024-07-15","conditions":["Narcolepsy Type 1","Narcolepsy With Cataplexy"],"enrollment":48,"completionDate":"2025-07-30"},{"nctId":"NCT05055024","phase":"PHASE2","title":"An Open Label Study of NLS-2 (Mazindol Extended Release) in Subjects With Narcolepsy","status":"COMPLETED","sponsor":"NLS Pharmaceutics","startDate":"2021-10-26","conditions":["Narcolepsy With Cataplexy","Narcolepsy","Narcolepsy Without Cataplexy"],"enrollment":52,"completionDate":"2023-01-19"},{"nctId":"NCT04923594","phase":"PHASE2","title":"Four-week Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in the Treatment of Narcolepsy","status":"COMPLETED","sponsor":"NLS Pharmaceutics","startDate":"2021-09-13","conditions":["Narcolepsy","Excessive Daytime Sleepiness","Cataplexy Narcolepsy"],"enrollment":67,"completionDate":"2022-06-30"},{"nctId":"NCT00000277","phase":"PHASE2","title":"Mazindol for Cocaine Abuse - 2","status":"COMPLETED","sponsor":"Yale University","startDate":"1994-09","conditions":["Cocaine-Related Disorders"],"enrollment":0,"completionDate":"1999-08"},{"nctId":"NCT02808104","phase":"PHASE2","title":"Mazindol Controlled Release in Adults With Attention Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"NLS Pharmaceutics","startDate":"2016-08","conditions":["Attention Deficit Disorder With Hyperactivity"],"enrollment":84,"completionDate":"2017-03-28"},{"nctId":"NCT00508677","phase":"","title":"Mazindol in Children With ADHD : Open-label, Efficacy, Safety and Pharmacokinetic Pilot Trial","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2008-03","conditions":["Attention Deficit Hyperactivity Disorder"],"enrollment":24,"completionDate":"2009-07"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"NUI":"N0000146368","MMSL":"1629","NDDF":"001874","UNII":"C56709M5NH","VUID":"4018025","CHEBI":"CHEBI:6702","VANDF":"4018025","INN_ID":"2895","RXNORM":"227434","UMLSCUI":"C0024977","chemblId":"CHEMBL781","ChEMBL_ID":"CHEMBL781","KEGG_DRUG":"D00367","DRUGBANK_ID":"DB00579","PUBCHEM_CID":"4020","SNOMEDCT_US":"387232005","IUPHAR_LIGAND_ID":"4797","MESH_DESCRIPTOR_UI":"D008454"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Novartis","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"93%"},"publicationCount":802,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"A08AA05","allCodes":["A08AA05"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Jan 27","pmid":"41745708","title":"Consensus Molecules Associated with Parkinson's Disease.","journal":"Neurology international"},{"date":"2026 Mar","pmid":"41667893","title":"Mazindol Immediate-Release/Sustained-Release (IR/SR): A 50-Year Legacy of Multifaceted Mechanisms and Emerging Therapeutic Potential.","journal":"Clinical drug investigation"},{"date":"2025 Oct-Dec","pmid":"41262092","title":"Preoperative Management with Mazindol for Obese Women Diagnosed with Endometrial Carcinoma Undergoing Robot-assisted Hysterectomy: A Pilot Case Series and Literature Review.","journal":"Gynecology and minimally invasive therapy"},{"date":"2026 Jan","pmid":"41130371","title":"Glucagon-like Peptide-1 Receptor Agonist Use and Risk of Cataract Development.","journal":"American journal of ophthalmology"},{"date":"2025 Dec 1","pmid":"41129133","title":"Glucagon-Like Peptide-1 Receptor Agonists and Age-Related Macular Degeneration.","journal":"JAMA ophthalmology"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Novartis","companyId":"","modality":"Small molecule","firstApprovalDate":"1973","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1973-06-14T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:46:09.147005+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}